Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources Group
Healthcare Reform Affects Market Access for Pharmaceutical Brands across Therapeutic Areas, According to Decision Resources Group
BURLINGTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Decision Resources Group, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that pharmaceutical companies are facing a paradigm shift in the way their brands gain access to the U.S. market, as Accountable Care Organizations (ACOs) continue to develop across the nation and enrollment on the health insurance exchanges moves forward.
"Through our comprehensive surveys of physicians and MCO executives, we're able to see how the enormous changes in the U.S. healthcare market are affecting pharmaceutical brands. When we looked at currently available and emerging brands by therapy, it was clear that some will benefit and others will be challenged," said Roy Moore, Senior Director at Decision Resources, a Decision Resources Group company. "For instance, looking at schizophrenia and depression, physician and payer responses suggest constrained use of branded therapies on exchange-based plans because of generic competition-even though they feel Abilify and Cymbalta will remain popular therapies. In light of the new dynamics shaping reimbursement decisions, pharmaceutical brand teams looking forward to 2014 vs. backward to 2013 will be crafting market access strategies that take changes like these into account."
ACOs, of which there are more than 500 across the US, will also impact prescribing behavior and brand uptake across therapies. For example, half of surveyed pulmonologists who participate in an ACO reduced their prescribing of the branded leukotriene inhibitor Singulair-while one-third assigned more of their patients to montelukast, a generic form of the same drug favored by ACO policies such as co-pay reductions. Similarly, 43% report they are less likely to prescribe Dulera because of their participation in an ACO whereas only 13% report increased prescribing of this agent. Yet the findings show that ACOs did not universally push physicians to generics-pulmonologists are evenly split in whether they increased or decreased prescribing of Advair (a competing combination therapy), highlighting how a brand can withstand the challenges stemming from new reimbursement models.
About Physician & Payer Forum Reports-2013 "Physician & Payer Dynamics" Series
U.S. Physician & Payer Forum is the industry's only syndicated primary market research product that includes insights from both physicians and HMO/PPO pharmacy directors to get a true sense of how both parties shape a market. The 2013 "Physician & Payer Dynamics" Series investigates how novel payer-led care coordination and financing programs impact prescribing behavior. The Series helps pharmaceutical brand managers and marketers develop effective market access strategies within the new paradigms brought about by Healthcare Reform. Find out more here.
2013 "Physician & Payer Dynamics" Report Titles:
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.
©2012 PR Newswire. All Rights Reserved.